Spine Takes Yuhan’s Peptide Into US Phase III For High-Need DDD
Second Asset In Global Pivotal Trials
Major Korean firm Yuhan is seeing progress across multiple novel drug candidates licensed out to global partners, with two now entering pivotal trials. An innovative therapy for degenerative disc disease licensed to Spine BioPharma has received an FDA nod for a Phase III program and may change the standard of care for chronic low back pain patients.
